Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...